EUCTR2009-009916-33-DE进行中（未招募）1 期
Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapy - DECIDER Trial
niversity Medical Center Freiburg0 个研究点目标入组 200 人开始时间: 2010年10月11日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent obtained according to international guidelines and local law;
- •2.Male or female patients aged > 60 years without upper age limit;
- •3.Patients with primary or secondary AML according to WHO (= 20% blasts in the peripheral blood (pB) or bone marrow (BM)) who are not expected to benefit from standard remission-induction chemotherapy;
- •4.Patients with < 30 000 leukocytes/µl;
- •5.Performance status ECOG 0, 1, 2;
- •6.Creatinine < 2.0 mg/dl (unless leukemia-related);
- •7.Ability to understand the nature of the study and the study related procedures and to comply with them.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 180
排除标准
- •1.AML of FAB subtype M3;
- •2.Previous remission-induction chemotherapy for MDS or AML, previous allografting;
- •3.Previous treatment with DAC, 5-azacytidine, VPA or another HDAC inhibitor, or ATRA;
- •4.Low-dose chemotherapy (e.g. hydroxyurea, cytosine arabinoside (Ara-C), melphalan, clofarabine etc.) within 4 weeks prior to DAC treatment, except for cytoreduction of leukocytosis = 30 000/µl with hydroxyurea or Ara-C as proscribed by the study protocol (section 7.3 and 7.4); the patient must have recovered from all clinically relevant reversible non-hematologic toxicities;
- •5.Treatment with tyrosine kinase inhibitors, immunomodulating agents (IMIDS) or other investigational AML treatment within the last 4 weeks or in a time period of drug half-life x 5 (whatever is shorter) before the first administration of DAC;
- •6.Treatment with cytokines within previous 4 weeks;
- •7.Concomitant therapy which is considered relevant for the evaluation of efficacy or safety of the trial drug (i.e. other chemo- or immunotherapy);
- •8.Other malignancy requiring treatment (previous chemotherapy for other malignancies is not an exclusion criteria);
- •9.Cardiac insufficiency NYHA IV;
- •10.Insufficient hepatic function (bilirubin, AST or ALT > = 2.5 x Upper Limit of Normal (ULN)) (unless leukemia-related);
- •11.Fatal hepatic function disorder during treatment with valproic acid in siblings;
- •12.Hepatic porphyria;
- •13.Manifest serious pancreatic function disorder;
- •14.Plasmatic coagulation disorder not related to AML;
- •15.Known active hepatitis B or C;
- •16.Known HIV infection;
- •17.Other uncontrolled active infections;
- •18.Known allergy against soy beans or peanuts;
- •19.Psychiatric disorder that interferes with treatment;
- •20.Patient without legal capacity who is unable to understand the nature, significance and consequences of the study;
- •21.Known hypersensitivity to, or intolerance of, one of the trial drugs, another retinoid or the excipients of the trial drugs;
- •22.Concomitant use of any other investigational drug or participation in a clinical trial within the last thirty days before the start of this study; simultaneous participation in registry and diagnostic trials is allowed;
- •23.Female patients who are pregnant or breast feeding;
- •24.Fertile patients refusing to use safe contraceptive methods during the study (for details see clinical trial protocol section 5.3);
- •25.Known or persistent abuse of medication, drugs or alcohol.
研究者
相似试验
已完成
2 期
Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapyC92.9Myeloid leukaemia, unspecifiedDRKS00000733niversitätsklinikum Freiburg204
已完成
2 期
Prospective randomized multicenter phase II study of pulmonalfiliae metastases (poor-prognosis) in clear cell renal cell carcinoma + / - adjuvant Sunitinibtherapie than 1 year - SMAT - AN 20/04kidney cancerC64C78.0Malignant neoplasm of kidney, except renal pelvisSecondary malignant neoplasm of lungDRKS00003518niversitätsklinikum Essen10
进行中（未招募）
1 期
Prospective Randomized Multicenter Phase II Trial toInvestigate Intensified Neoadjuvant Chemotherapy inLocally Advanced Pancreatic Cancerocally advanced pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2013-004796-12-DEAIO-Studien-gGmbH168
进行中（未招募）
1 期
Randomized, multi-center phase II clinical trial for the regeneration of cartilage lesions in the knee using nasal chondrocyte-based tissue (N-TEC) or nasal chondrocyte-based cell- (N-CAM) therapiesPatients must display 1-2 symptomatic, focal cartilage lesion grade IIIIV(according to the grading by the International Cartilage RepairSociety (ICRS)) from 2 to 8 cm2 on the femoral condyle and/or thetrochlea, have to be between 18-65 years old and must consent in oraland written manner in order to be enrolled in the study.EUCTR2015-005162-34-HRniversity Hospital Basel108
进行中（未招募）
1 期
Randomized, multi-center phase II clinical trial for the regeneration of cartilage lesions in the knee using nasal chondrocyte-based tissue (N-TEC) or nasal chondrocyte-based cell- (N-CAM) therapiesPatients must display 1-2 symptomatic, focal cartilage lesion grade IIIIV(according to the grading by the International Cartilage RepairSociety (ICRS)) from 2 to 8 cm2 on the femoral condyle and/or thetrochlea, have to be between 18-65 years old and must consent in oraland written manner in order to be enrolled in the study.MedDRA version: 20.0Level: LLTClassification code 10072638Term: Articular cartilage defectSystem Organ Class: 100000004859EUCTR2015-005162-34-DEniversity Hospital Basel108